| Market Cap | 4.93M | P/E | - | EPS this Y | 20.30% | Ern Qtrly Grth | - |
| Income | -6.14M | Forward P/E | -0.35 | EPS next Y | 11.10% | 50D Avg Chg | -13.00% |
| Sales | 839.36k | PEG | -0.64 | EPS past 5Y | - | 200D Avg Chg | -86.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | 1.00% | 52W High Chg | -96.00% |
| Recommedations | 2.00 | Quick Ratio | 1.41 | Shares Outstanding | 14.24M | 52W Low Chg | 1.00% |
| Insider Own | 0.07% | ROA | -39.97% | Shares Float | 10.49M | Beta | 1.85 |
| Inst Own | 2.70% | ROE | -23,783.76% | Shares Shorted/Prior | 839.19K/67.71K | Price | 0.61 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 948,025 | Target Price | 3.50 |
| Oper. Margin | -873.27% | Earnings Date | May 13 | Volume | 71,082 | Change | -2.03% |
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Straube Richard | SENIOR VICE PRESIDEN.. SENIOR VICE PRESIDENT AND CMO | May 18 | Buy | 0.5000 | 8,000 | 4,000 | 8,000 | 05/18/22 |
| SCHABER CHRISTOPHER J | CHAIRMAN, CEO AND PR.. CHAIRMAN, CEO AND PRESIDENT | May 18 | Buy | 0.4433 | 20,000 | 8,866 | 90,095 | 05/18/22 |